LILLY Australia has announced the Australian Government's decision to list its interleukin-17A (IL-17A) inhibitor, TALTZ (ixekizumab), on the Pharmaceutical Benefits Scheme (PBS), Authority Required, for adult patients with severe psoriatic arthritis (PsA) as monotherapy or in combination with cDMARDs in adult patients under certain conditions.
Effective 01 Mar, TALTZ will be reimbursed on the PBS for eligible Australian patients with severe PsA.
Available as an authority required listing, TALTZ is administered by subcutaneous injection, delivered via an auto-injector.
University of Queensland Associate Professor Peter Nash welcomed the news saying, "Joint damage can be progressive in psoriatic arthritis with increased disability and reduced quality of life.
"It is important that patients have access to alternate therapies to help improve disease control."
Visit ebs.tga.gov.au for the PI.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Mar 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Mar 19
